keyword
MENU ▼
Read by QxMD icon Read
search

Tau and PET

keyword
https://www.readbyqxmd.com/read/28507319/longitudinal-changes-of-tau-pet-imaging-in-relation-to-hypometabolism-in-prodromal-and-alzheimer-s-disease-dementia
#1
K Chiotis, L Saint-Aubert, E Rodriguez-Vieitez, A Leuzy, O Almkvist, I Savitcheva, M Jonasson, M Lubberink, A Wall, G Antoni, A Nordberg
The development of tau-specific positron emission tomography (PET) tracers allows imaging in vivo the regional load of tau pathology in Alzheimer's disease (AD) and other tauopathies. Eighteen patients with baseline investigations enroled in a 17-month follow-up study, including 16 with AD (10 had mild cognitive impairment and a positive amyloid PET scan, that is, prodromal AD, and six had AD dementia) and two with corticobasal syndrome. All patients underwent PET scans with [(18)F]THK5317 (tau deposition) and [(18)F]FDG (glucose metabolism) at baseline and follow-up, neuropsychological assessment at baseline and follow-up and a scan with [(11)C]PIB (amyloid-β deposition) at baseline only...
May 16, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28500751/radiological-biomarkers-for-diagnosis-in-psp-where-are-we-and-where-do-we-need-to-be
#2
REVIEW
Jennifer L Whitwell, Günter U Höglinger, Angelo Antonini, Yvette Bordelon, Adam L Boxer, Carlo Colosimo, Thilo van Eimeren, Lawrence I Golbe, Jan Kassubek, Carolin Kurz, Irene Litvan, Alexander Pantelyat, Gil Rabinovici, Gesine Respondek, Axel Rominger, James B Rowe, Maria Stamelou, Keith A Josephs
BACKGROUND: PSP is a pathologically defined neurodegenerative tauopathy with a variety of clinical presentations including typical Richardson's syndrome and other variant PSP syndromes. Our aim was to critically evaluate the degree to which structural, functional and molecular neuroimaging metrics fulfill criteria for diagnostic biomarkers of PSP. METHODS: We queried the PubMed, Cochrane, Medline, and PSYCInfo databases for original research articles published in English using postmortem diagnosis or NINDS-SPSP criteria as the diagnostic standard from 1996-2016...
May 13, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28487650/neuropsychological-testing-and-machine-learning-distinguish-alzheimer-s-disease-from-other-causes-for-cognitive-impairment
#3
Pavel Gurevich, Hannes Stuke, Andreas Kastrup, Heiner Stuke, Helmut Hildebrandt
With promising results in recent treatment trials for Alzheimer's disease (AD), it becomes increasingly important to distinguish AD at early stages from other causes for cognitive impairment. However, existing diagnostic methods are either invasive (lumbar punctures, PET) or inaccurate Magnetic Resonance Imaging (MRI). This study investigates the potential of neuropsychological testing (NPT) to specifically identify those patients with possible AD among a sample of 158 patients with Mild Cognitive Impairment (MCI) or dementia for various causes...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28456479/age-specific-and-sex-specific-prevalence-of-cerebral-%C3%AE-amyloidosis-tauopathy-and-neurodegeneration-in-cognitively-unimpaired-individuals-aged-50-95-years-a-cross-sectional-study
#4
Clifford R Jack, Heather J Wiste, Stephen D Weigand, Terry M Therneau, David S Knopman, Val Lowe, Prashanthi Vemuri, Michelle M Mielke, Rosebud O Roberts, Mary M Machulda, Matthew L Senjem, Jeffrey L Gunter, Walter A Rocca, Ronald C Petersen
BACKGROUND: A new classification for biomarkers in Alzheimer's disease and cognitive ageing research is based on grouping the markers into three categories: amyloid deposition (A), tauopathy (T), and neurodegeneration or neuronal injury (N). Dichotomising these biomarkers as normal or abnormal results in eight possible profiles. We determined the clinical characteristics and prevalence of each ATN profile in cognitively unimpaired individuals aged 50 years and older. METHODS: All participants were in the Mayo Clinic Study of Aging, a population-based study that uses a medical records linkage system to enumerate all individuals aged 50-89 years in Olmsted County, MN, USA...
June 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28441967/comparison-of-csf-markers-and-semi-quantitative-amyloid-pet-in-alzheimer-s-disease-diagnosis-and-in-cognitive-impairment-prognosis-using-the-adni-2-database
#5
Fayçal Ben Bouallègue, Denis Mariano-Goulart, Pierre Payoux
BACKGROUND: The relative performance of semi-quantitative amyloid positron emission tomography (PET) and cerebrospinal fluid (CSF) markers in diagnosing Alzheimer's disease (AD) and predicting the cognitive evolution of patients with mild cognitive impairment (MCI) is still debated. METHODS: Subjects from the Alzheimer's Disease Neuroimaging Initiative 2 with complete baseline cognitive assessment (Mini Mental State Examination, Clinical Dementia Rating [CDR] and Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-cog] scores), CSF collection (amyloid-β1-42 [Aβ], tau and phosphorylated tau) and (18)F-florbetapir scans were included in our cross-sectional cohort...
April 26, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28440890/fluorescence-and-autoradiographic-evaluation-of-tau-pet-ligand-pbb3-to-%C3%AE-synuclein-pathology
#6
Shunsuke Koga, Maiko Ono, Naruhiko Sahara, Makoto Higuchi, Dennis W Dickson
BACKGROUND: The tau PET ligand 2-((1E,3E)-4-(6-([(11) C]methylamino)pyridin-3-yl)buta-1,3-dienyl)benzo[d]thiazol-6-ol ([(11) C]PBB3) binds to a wide range of tau pathology; however, binding property of PBB3 to non-tau inclusions remains unknown. To clarify whether [(11) C]PBB3 binds to α-synuclein pathology, reactivity of PBB3 was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from α-synucleinopathies patients. METHOD: Of 10 pure Lewy body disease and 120 multiple system atrophy (MSA) cases in the Mayo Clinic brain bank, we selected 3 Lewy body disease and 4 MSA cases with a range of α-synuclein severity based on the quantitative analysis of α-synuclein burden...
April 25, 2017: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/28422821/how-the-cognitive-reserve-interacts-with-%C3%AE-amyloid-deposition-in-mitigating-fdg-metabolism-an-observational-study
#7
Elena Carapelle, Laura Serra, Sergio Modoni, Michele Falcone, Carlo Caltagirone, Marco Bozzali, Luigi Maria Specchio, Carlo Avolio
This observational study had the aim to assess the interaction between cognitive reserve (CR) and cerebrospinal fluid β-amyloid1-42 (Aβ1-42) in modulating brain [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) metabolism in patients with moderate Alzheimer disease (AD).Twenty-seven patients with probable AD and 25 neurological normal subjects (NNS) entered the study. All participants had an FDG-PET scan, and AD patients also received a lumbar puncture to measure Aβ1-42, 181p-tau, and Tau concentrations...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28415771/11c-choline-pet-ct-and-whole-body-mri-including-diffusion-weighted-imaging-for-patients-with-recurrent-prostate-cancer
#8
Hinrich Wieder, Ambros J Beer, Konstantin Holzapfel, Martin Henninger, Tobias Maurer, Sarah Schwarzenboeck, Ernst J Rummeny, Matthias Eiber, Jens Stollfuss
PURPOSE: To compare the detection efficacy of 11C-choline positron emission tomography and computed tomography (PET/CT) with whole-body magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) in patients with suspected recurrent prostate cancer. MATERIAL AND METHODS: Fifty-seven patients (mean age 68, range 54-80 years) underwent 11C-choline PET/CT and MRI using T1-weighted (T1w), short-tau inversion recovery (STIR), and DWI. Two readers visually rated suspicious lesions on a 5-point scale in 20 different regions...
March 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28408865/tau-pathology-distribution-in-alzheimer-s-disease-corresponds-differentially-to-cognition-relevant-functional-brain-networks
#9
Oskar Hansson, Michel J Grothe, Tor Olof Strandberg, Tomas Ohlsson, Douglas Hägerström, Jonas Jögi, Ruben Smith, Michael Schöll
Neuropathological studies have shown that the typical neurofibrillary pathology of hyperphosphorylated tau protein in Alzheimer's disease (AD) preferentially affects specific brain regions whereas others remain relatively spared. It has been suggested that the distinct regional distribution profile of tau pathology in AD may be a consequence of the intrinsic network structure of the human brain. The spatially distributed brain regions that are most affected by the spread of tau pathology may hence reflect an interconnected neuronal system...
2017: Frontiers in Neuroscience
https://www.readbyqxmd.com/read/28404803/neuropsychiatric-symptoms-predict-hypometabolism-in-preclinical-alzheimer-disease
#10
Kok Pin Ng, Tharick A Pascoal, Sulantha Mathotaarachchi, Chang-Oh Chung, Andréa L Benedet, Monica Shin, Min Su Kang, Xiaofeng Li, Maowen Ba, Nagaendran Kandiah, Pedro Rosa-Neto, Serge Gauthier
OBJECTIVE: To identify regional brain metabolic dysfunctions associated with neuropsychiatric symptoms (NPS) in preclinical Alzheimer disease (AD). METHODS: We stratified 115 cognitively normal individuals into preclinical AD (both amyloid and tau pathologies present), asymptomatic at risk for AD (either amyloid or tau pathology present), or healthy controls (no amyloid or tau pathology present) using [(18)F]florbetapir PET and CSF phosphorylated tau biomarkers...
May 9, 2017: Neurology
https://www.readbyqxmd.com/read/28394771/tau-pet-binding-distinguishes-patients-with-early-stage-posterior-cortical-atrophy-from-amnestic-alzheimer-disease-dementia
#11
Gregory S Day, Brian A Gordon, Kelley Jackson, Jon J Christensen, Maria Rosana Ponisio, Yi Su, Beau M Ances, Tammie L S Benzinger, John C Morris
BACKGROUND: Flortaucipir (tau) positron emission tomography (PET) binding distinguishes individuals with clinically well-established posterior cortical atrophy (PCA) due to Alzheimer disease (AD) from cognitively normal (CN) controls. However, it is not known whether tau-PET binding patterns differentiate individuals with PCA from those with amnestic AD, particularly early in the symptomatic stages of disease. METHODS: Flortaucipir and florbetapir (β-amyloid) PET imaging were performed in individuals with early-stage PCA (N=5), amnestic AD dementia (N=22), and CN controls (N=47)...
April 7, 2017: Alzheimer Disease and Associated Disorders
https://www.readbyqxmd.com/read/28374171/quantification-of-tau-load-using-18-f-av1451-pet
#12
Sandeep S V Golla, Tessa Timmers, Rik Ossenkoppele, Colin Groot, Sander Verfaillie, Philip Scheltens, Wiesje M van der Flier, Lothar Schwarte, Mark A Mintun, Michael Devous, Robert C Schuit, Albert D Windhorst, Adriaan A Lammertsma, Ronald Boellaard, Bart N M van Berckel, Maqsood Yaqub
PURPOSE: The tau tracer [(18)F]AV1451, also known as flortaucipir, is a promising ligand for imaging tau accumulation in Alzheimer's disease (AD). Most of the previous studies have quantified tau load using standardized uptake value ratios (SUVr) derived from a static [(18)F]AV1451 scan. SUVr may, however, be flow dependent and, especially for longitudinal studies, should be validated against a fully quantitative approach. The objective of this study was to identify the optimal tracer kinetic model for measuring tau load using [(18)F]AV1451...
April 3, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28359327/monoamine-oxidase-b-inhibitor-selegiline-reduces-18-f-thk5351-uptake-in-the-human-brain
#13
Kok Pin Ng, Tharick A Pascoal, Sulantha Mathotaarachchi, Joseph Therriault, Min Su Kang, Monica Shin, Marie-Christine Guiot, Qi Guo, Ryuichi Harada, Robert A Comley, Gassan Massarweh, Jean-Paul Soucy, Nobuyuki Okamura, Serge Gauthier, Pedro Rosa-Neto
BACKGROUND: (18)F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of (18)F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on (18)F-THK5351 brain uptake using PET and autoradiography...
March 31, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28349119/a-multinational-study-distinguishing-alzheimer-s-and-healthy-patients-using-cerebrospinal-fluid-tau-a%C3%AE-42-cutoff-with-concordance-to-amyloid-positron-emission-tomography-imaging
#14
Yi Mo, Julie Stromswold, Kimberly Wilson, Daniel Holder, Cyrille Sur, Omar Laterza, Mary J Savage, Arie Struyk, Philip Scheltens, Charlotte E Teunissen, James Burke, S Lance Macaulay, Geir Bråthen, Sigrid Botne Sando, Linda R White, Christy Weiss, Arturo Cowes, Michele M Bush, Ganga DeSilva, David G Darby, Stephanie R Rainey-Smith, Jackie Surls, Eileen Sagini, Michael Tanen, Amy Altman, Johan Luthman, Michael F Egan
INTRODUCTION: Changes in cerebrospinal fluid (CSF) tau and amyloid β (Aβ)42 accompany development of Alzheimer's brain pathology. Robust tau and Aβ42 immunoassays were developed to establish a tau/Aβ42 cutoff distinguishing mild-to-moderate Alzheimer's disease (AD) subjects from healthy elderly control (HC) subjects. METHODS: A CSF tau/Aβ42 cutoff criteria was chosen, which distinguished the groups and maximized concordance with amyloid PET. Performance was assessed using an independent validation cohort...
2017: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
https://www.readbyqxmd.com/read/28336780/biodistribution-and-radiation-dosimetry-for-the-tau-tracer-18-f-thk-5351-in-healthy-human-subjects
#15
Ing-Tsung Hsiao, Kun-Ju Lin, Kuo-Lun Huang, Chin-Chang Huang, Han-Shiuan Chen, Shiaw-Pyng Wey, Tzu-Chen Yen, Nobuyuki Okamura, Jung-Lung Hsu
(18)F-THK-5351 is a novel radiotracer that demonstrates high binding selectivity and affinity for tau pathology and exhibits better pharmacokinetics in the living brain than previous THK tau probes. The aim of the present study was to estimate the radiation dose of (18)F-THK-5351 in humans and to compare the clinical radiation dosimetry results to estimations published previously with preclinical data. Methods: Serial whole-body positron emission tomography/computed tomography (PET/CT) imaging was performed for 240 min on 12 healthy volunteers after injecting (18)F-THK-5351 (mean administered activity: 377...
March 23, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28334939/association-between-tau-deposition-and-antecedent-amyloid-%C3%AE-accumulation-rates-in-normal-and-early-symptomatic-individuals
#16
Duygu Tosun, Susan Landau, Paul S Aisen, Ronald C Petersen, Mark Mintun, William Jagust, Michael W Weiner
A long-term goal of our field is to determine the sequence of pathological events, which ultimately lead to cognitive decline and dementia. In this study, we first assessed the patterns of brain tau tangle accumulation (measured with the positron emission tomography tracer 18F-AV-1451) associated with well-established Alzheimer's disease factors in a cohort including cognitively healthy elderly individuals and individuals at early symptomatic stages of Alzheimer's disease. We then explored highly associated patterns of greater 18F-AV-1451 binding and increased annualized change in cortical amyloid-β plaques measured as florbetapir positron emission tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to what extent these multimodal pattern associations explained the variance in cognitive performance and clinical outcome measures, independently and jointly...
March 17, 2017: Brain: a Journal of Neurology
https://www.readbyqxmd.com/read/28315409/in-vivo-tau-pet-imaging-in-dementia-pathophysiology-radiotracer-quantification-and-a-systematic-review-of-clinical-findings
#17
REVIEW
Benjamin Hall, Elijah Mak, Simon Cervenka, Franklin I Aigbirhio, James B Rowe, John T O'Brien
In addition to the deposition of β-amyloid plaques, neurofibrillary tangles composed of aggregated hyperphosphorylated tau are one of the pathological hallmarks of Alzheimer's disease and other neurodegenerative disorders. Until now, our understanding about the natural history and topography of tau deposition has only been based on post-mortem and cerebrospinal fluid studies, and evidence continues to implicate tau as a central driver of downstream neurodegenerative processes and cognitive decline. Recently, it has become possible to assess the regional distribution and severity of tau burden in vivo with the development of novel radiotracers for positron emission tomography (PET) imaging...
March 15, 2017: Ageing Research Reviews
https://www.readbyqxmd.com/read/28314821/phases-of-hyperconnectivity-and-hypoconnectivity-in-the-default-mode-and-salience-networks-track-with-amyloid-and-tau-in-clinically-normal-individuals
#18
Aaron P Schultz, Jasmeer P Chhatwal, Trey Hedden, Elizabeth C Mormino, Bernard J Hanseeuw, Jorge Sepulcre, Willem Huijbers, Molly LaPoint, Rachel F Buckley, Keith A Johnson, Reisa A Sperling
Alzheimer's disease (AD) is characterized by two hallmark molecular pathologies: amyloid aβ1-42 and Tau neurofibrillary tangles. To date, studies of functional connectivity MRI (fcMRI) in individuals with preclinical AD have relied on associations with in vivo measures of amyloid pathology. With the recent advent of in vivo Tau-PET tracers it is now possible to extend investigations on fcMRI in a sample of cognitively normal elderly humans to regional measures of Tau. We modeled fcMRI measures across four major cortical association networks [default-mode network (DMN), salience network (SAL), dorsal attention network, and frontoparietal control network] as a function of global cortical amyloid [Pittsburgh Compound B (PiB)-PET] and regional Tau (AV1451-PET) in entorhinal, inferior temporal (IT), and inferior parietal cortex...
April 19, 2017: Journal of Neuroscience: the Official Journal of the Society for Neuroscience
https://www.readbyqxmd.com/read/28303915/brain-imaging-applications-of-tau-pet-imaging
#19
Nobuyuki Okamura, Kazuhiko Yanai
No abstract text is available yet for this article.
March 17, 2017: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/28302766/csf-clearance-in-alzheimer-disease-measured-with-dynamic-pet
#20
Mony J de Leon, Yi Li, Nobuyuki Okamura, Wai H Tsui, Les A Saint Louis, Lidia Glodzik, Ricardo S Osorio, Juan Fortea, Tracy Butler, Elizabeth Pirraglia, Silvia Fossati, Hee-Jin Kim, Roxana O Carare, Maiken Nedergaard, Helene Benveniste, Henry Rusinek
Evidence supporting the hypothesis that reduced cerebrospinal fluid (CSF) clearance is involved in the pathophysiology of Alzheimer's disease (AD) comes from primarily from rodent models. However, unlike rodents where predominant extra-cranial CSF egress is via olfactory nerves traversing the cribriform plate, human CSF clearance pathways are not well characterized. Using dynamic Positron Emission Tomography (PET) with (18)F-THK5117 a tracer for tau pathology, the ventricular CSF time activity was used as a biomarker for CSF clearance...
March 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
114281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"